« Back



Monday April 03 2017 12:24 PM

New treatment option available to help Irish Patients in fight against Multiple Sclerosis (MS)

Daclizumab has a ‘double-action’ approach – offering a new once-monthly treatment option for people living with MS in Ireland.

A new once-monthly treatment for relapsing multiple sclerosis (MS) that uniquely targets the immune system is now reimbursed in Ireland to help in the fight against this devastating disease. 

The new medicine, named daclizumab, can be self-administered monthly at home and has been approved for reimbursement by the Health Service Executive (HSE). 

Two Irish hospitals – St Vincent’s University Hospital Dublin and Beaumont Hospital Dublin -  were part of an international research team carrying out the largest clinical trial ever reported in MS, called DECIDE. 

This trial demonstrated daclizumab’s ability to reduce the frequency of relapses (attack of symptoms) as well as the risk of disease progression, compared to the widely-used MS medication interferon beta-1a. 

Ms Ava Battles, Chief Executive of MS Ireland, welcomes daclizumab’s availability and reimbursement in Ireland: “The authorisation of daclizumab is another step forward in the fight against MS, offering hope to those living with the condition. The fact that it works in a different way to other therapies not only furthers our understanding of this complex disease, but also importantly gives people with MS, and doctors in Ireland, an additional treatment option to consider - which is vital because the course of the condition can be so different from person to person.”

How does daclizumab work?

Daclizumab is thought to work by targeting and blocking the growth of activated T cells, which are known to gradually damage myelin, and eventually damage the central nervous system (CNS). Additionally, daclizumab increases the number of natural killer cells in the body, strengthening their natural ability to find and kill existing activated T cells. By rebalancing the immune system, daclizumab is thought to help protect against damage within the CNS. Clinical studies have shown that daclizumab positively impacts relapse rates, disability progression, brain lesions (detected through MRI scans), and cognitive function in MS, along with a generally manageable safety profile.

Michael O’Connell, Country Director of Biogen Ireland, said: “We are pleased to offer daclizumab as an additional treatment option for relapsing forms of MS in Ireland. Great innovation in the MS field has taken place in recent years, but we still have too many patients falling short of optimal health outcomes. We have a responsibility as a company with great heritage in this area to continue our search for pharmacological solutions whilst also supporting the MS community more broadly.”

Further reading

For more information on daclizumab including details of the clinical trial results, download Biogen's information sheet/press release.

Author: Biogen

Tags: daclizumab, relapsing, ms, multiplesclerosis



Friday April 28 2017 12:43

This sound amazing, I am very keen to learn more !


Friday May 19 2017 23:21

I'm starting on this next month

Add a comment

Your email address will not be published and will only be used by MS Ireland to contact you should there be an issue with your comment.

Please read our policy on making comments. Basically, respect other people’s view, use appropriate language and be nice! Comments are published between 9am and 5pm, Monday to Friday.

We ask this question to ensure that you are a real person, and not a computer adding information automatically.

By commenting, you are adhering to our Terms of use / Privacy

Latest News

More news

What's hot


We're Hiring

If you would like to be part of our team, take a look at our current job opportunities.

Find out more

Events Calendar

» Our next Event

24 October 2018: Group led physiotherapy classes for people with MS, starts 3rd October.

View all events


If you'd like to receive e-news updates from The Society please enter your email address below. If you want to know more about how we manage personal data then please see our privacy policy.

My local MSI

Map of MS Ireland's service areas South Mid West West Midlands South East North East North West North Dublin City and Fingal South West Dublin and Kildare South East Dublin and Wicklow